NASDAQ:BCTX BriaCell Therapeutics (BCTX) Stock Price, News & Analysis → If you have $2,500 bucks… check this out (From DTI) (Ad) Free BCTX Stock Alerts $2.17 -0.07 (-3.13%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.11▼$2.2950-Day Range$2.02▼$3.5752-Week Range$2.01▼$7.59Volume36,051 shsAverage Volume47,456 shsMarket Capitalization$34.68 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get BriaCell Therapeutics alerts: Email Address BriaCell Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside707.2% Upside$18.00 Price TargetShort InterestBearish4.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.39) to ($1.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.91 out of 5 starsMedical Sector816th out of 913 stocksPharmaceutical Preparations Industry382nd out of 423 stocks 3.5 Analyst's Opinion Consensus RatingBriaCell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBriaCell Therapeutics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.88% of the float of BriaCell Therapeutics has been sold short.Short Interest Ratio / Days to CoverBriaCell Therapeutics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in BriaCell Therapeutics has recently increased by 1.05%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBriaCell Therapeutics does not currently pay a dividend.Dividend GrowthBriaCell Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCTX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for BriaCell Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for BCTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added BriaCell Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BriaCell Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.77% of the stock of BriaCell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.42% of the stock of BriaCell Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for BriaCell Therapeutics are expected to decrease in the coming year, from ($1.39) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BriaCell Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BriaCell Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About BriaCell Therapeutics Stock (NASDAQ:BCTX)BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Read More BCTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCTX Stock News HeadlinesApril 24, 2024 | globenewswire.comBriaCell Announces Oral and Poster Presentations at ASCO 2024April 10, 2024 | globenewswire.comBriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate CancerApril 27, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…April 9, 2024 | finance.yahoo.comBriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACRMarch 20, 2024 | sg.finance.yahoo.comBriaCell Therapeutics Corp. (BCTX)March 7, 2024 | globenewswire.comBriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer ImmunotherapiesMarch 6, 2024 | globenewswire.comBriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR ConferenceFebruary 27, 2024 | finance.yahoo.comBriaCell Provides Update on Alleged Illegal Trading of Public SecuritiesApril 27, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…February 27, 2024 | globenewswire.comBriaCell Provides Update on Alleged Illegal Trading of Public SecuritiesFebruary 14, 2024 | finance.yahoo.comBriaCell Therapeutics Corp. (BCTX) stock forecast and price targetJanuary 30, 2024 | finance.yahoo.comBriaCell Therapeutics Corp. Announces Results of Shareholder MeetingDecember 28, 2023 | finance.yahoo.comBriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer PatientsDecember 27, 2023 | benzinga.comBriaCell Therapeutics Stock (NASDAQ:BCTX) Dividends: History, Yield and DatesDecember 20, 2023 | msn.comBriaCell Therapeutics' Cancer Drug Shows Preliminary Survival, Clinical Benefit In Pretreated PatientsDecember 20, 2023 | finance.yahoo.comBriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient SubsetDecember 6, 2023 | finance.yahoo.comBriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCSNovember 8, 2023 | finance.yahoo.comBCTX: November 2023 SITC PosterNovember 4, 2023 | morningstar.comBriaCell Therapeutics Corp Ordinary Shares - New BCTXNovember 1, 2023 | finance.yahoo.comBCTX: Year in ReviewOctober 24, 2023 | morningstar.comBriaCell Therapeutics Corp Ordinary Shares - NewOctober 11, 2023 | finance.yahoo.comBriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT™ Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo ClinicAugust 31, 2023 | finance.yahoo.comBriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing ShareholdersAugust 31, 2023 | finance.yahoo.comBriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast CancerAugust 28, 2023 | bizjournals.comBriaCell receives court approval to launch spinoff aimed at accelerating cancer drug developmentJuly 10, 2023 | finance.yahoo.comBCTX: Pivotal Study Protocol ClearedJune 28, 2023 | benzinga.comHC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $25 Price TargetSee More Headlines Receive BCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today4/27/2024Next Earnings (Estimated)6/12/2024Fiscal Year End7/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BCTX CUSIPN/A CIK1610820 Webwww.briacell.com Phone(604) 921-1810Fax604-921-1898Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$18.00 Low Stock Price Target$18.00 Potential Upside/Downside+707.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,300,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-57.48% Debt Debt-to-Equity RatioN/A Current Ratio2.99 Quick Ratio2.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.24) per share Price / Book-9.29Miscellaneous Outstanding Shares15,980,000Free Float12,503,000Market Cap$35.64 million OptionableOptionable Beta1.02 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. William V. Williams M.D. (Age 69)CEO, President & Director Comp: $785.3kMr. Gadi Levin B.Com. (Age 51)C.A., CPA, M.B.A., CFO & Corporate Secretary Comp: $304.46kDr. Miguel A. Lopez-Lago Ph.D. (Age 55)Chief Scientific Officer Comp: $298.9kDr. Giuseppe Del Priore M.D. (Age 62)M.P.H., MPH, Chief Medical Officer Comp: $492.5kDr. Charles Louis Wiseman FACP (Age 78)M.D., Founder, Principal Research Advisor & Member of Scientific Advisory Board Comp: $241.14kKey CompetitorsUnicycive TherapeuticsNASDAQ:UNCYXilio TherapeuticsNASDAQ:XLOOcuphire PharmaNASDAQ:OCUPCara TherapeuticsNASDAQ:CARAJanOneNASDAQ:JANView All CompetitorsInstitutional OwnershipK.J. Harrison & Partners IncBought 6,329 shares on 4/27/2024Ownership: 0.545%Wasatch Advisors LPSold 246,351 shares on 2/14/2024Ownership: 1.673%Redmond Asset Management LLCSold 4,270 shares on 2/12/2024Ownership: 0.836%National Bank of Canada FIBought 5,000 shares on 2/6/2024Ownership: 0.047%Simplex Trading LLCBought 200 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions BCTX Stock Analysis - Frequently Asked Questions Should I buy or sell BriaCell Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BriaCell Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCTX shares. View BCTX analyst ratings or view top-rated stocks. What is BriaCell Therapeutics' stock price target for 2024? 1 equities research analysts have issued twelve-month price objectives for BriaCell Therapeutics' stock. Their BCTX share price targets range from $18.00 to $18.00. On average, they anticipate the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 707.2% from the stock's current price. View analysts price targets for BCTX or view top-rated stocks among Wall Street analysts. How have BCTX shares performed in 2024? BriaCell Therapeutics' stock was trading at $5.85 on January 1st, 2024. Since then, BCTX stock has decreased by 61.9% and is now trading at $2.23. View the best growth stocks for 2024 here. When is BriaCell Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024. View our BCTX earnings forecast. How were BriaCell Therapeutics' earnings last quarter? BriaCell Therapeutics Corp. (NASDAQ:BCTX) announced its quarterly earnings data on Monday, March, 18th. The company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.51. When did BriaCell Therapeutics IPO? BriaCell Therapeutics (BCTX) raised $15 million in an IPO on Wednesday, February 24th 2021. The company issued 3,300,000 shares at a price of $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. Who are BriaCell Therapeutics' major shareholders? BriaCell Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include K.J. Harrison & Partners Inc (0.54%). View institutional ownership trends. How do I buy shares of BriaCell Therapeutics? Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCTX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
